Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD11301 Gel in Early Stage CTCL
NCT03292406Phase 2Completed
- Sponsor
- Galderma
- Start
- Dec 2017
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of resiquimod in cutaneous T-cell lymphoma (CTCL) (3 arms), sponsored by Galderma. Primary endpoint: Overall Response of Target Treated Lesions Based on Modified Composite Assessment of Index Lesion Severity at 12 weeks. Started Dec 2017; status: completed.
02
Drugs
resiquimod
03
Conditions
cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT03292406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03292406.